AbCellera has announced an expanded collaboration with Denali Therapeutics Inc. to discover antibodies as therapies for neurological indications.    AbCellera will generate panels of antibodies for up to eight drug targets nominated by Denali using AbCellera’s high-throughput, ultra-deep single-cell immune profiling capabilities. This multi-target deal expands the scope of the initial collaboration, announced in June 2018, that successfully produced potent lead candidates now in preclini...